Portico

EXCELLENT
TAVI OUTCOMES

  • Prof. Steve Worthley
  • We Get Great Results
    Prof. Steve Worthley, Royal Adelaide Hospital, Australia

    With Portico “you can get it in the right spot the first time, most of the time . . . and it’s repositionable [when required]. It’s also simple and straightforward, and I know that I can have low pacing rates, low paravalvular leak, and good vascular access results. So it’s great for patients and it’s easy to use.”

Portico Valve Outcomes1

In the Portico I trial, 941 high-risk patients revealed excellent 30-day outcomes during transcatheter aortic valve implantation (TAVI).

Portico Valve Outcomes1

In the Portico I trial, 941 high-risk patients revealed excellent 30-day outcomes during transcatheter aortic valve implantation (TAVI).

*A new permanent pacemaker was implanted in 161 patients, representing 17.1% of all patients regardless of pacemaker status at baseline and 18.7% of patients with no prior pacemaker.

  • Low Aortic Gradient

    The Portico I study also revealed a significantly reduced, single-digit mean aortic gradient—8.6 mmHg at 30 days and 8.7 mmHg at 1 year—post TAVI procedure.1

    The Portico I study also revealed a significantly reduced, single-digit mean aortic gradient—8.6 mmHg at 30 days and 8.7 mmHg at 1 year—post TAVI procedure.1

  • Low Paravalvular Leak With Portico Valve

    Similarly, there was a very low clinically significant paravalvular leak (PVL) compared to baseline (N = 524).1
     

    Similarly, there was a very low clinically significant paravalvular leak (PVL) compared to baseline (N = 524).1
     

  • SIGNIFICANT IMPROVEMENT IN NYHA CLASS

    At 1 year post TAVI with the Portico valve there was a significant improvement in New York Heart Association (NYHA) class (N = 673).1

     

    At 1 year post TAVI with the Portico valve there was a significant improvement in New York Heart Association (NYHA) class (N = 673).1

AP2947036-WBO Rev. A

References
  1. Søndergaard L, et al. One-year outcomes with a self-expanding, repositionable transcatheter heart valve in severe aortic stenosis patients: PORTICO-I. J Am Coll Cardiol. 2018. Epub before print. doi: 10.1016/j.jacc.2018.09.014.
     

This site uses cookies to improve your experience.

To find out more please read our Privacy and Cookies policy.

Ok

Sign up

Receive updates from Abbott Structural Heart

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.